论文部分内容阅读
完全切除的非小细胞肺癌手术后是否采用辅助化疗一直存在很大争议,然而面对完全切除的非小细胞肺癌5年生存率现状(Ⅰ期57％-67％:Ⅱ期38％～55％:ⅢA期23％-25％Clifton F Mountain 1997年),半数或超过半数的完全切除的NSCLC术后5年内由于局部复发和远道转移而死亡,任何一个从事肿瘤治疗的临床医师都不可能无动于衷、无所作为。问题是现有的治疗是否能够给患者提供生存益处?答案就要从循证医学,从最新的临床大样本、多中心、随机对照研究中寻找。本文“非小细胞肺癌完全切除术后含铂辅助化疗方案的累计Meta分析”以严谨科学的态度、翔实丰富的资料、恰当有效的分析方法(累计Meta分析)对根治性非小细胞肺癌术后是否采用辅助化疗进行了分析并得出初步结论。对临床
However, it remains controversial whether adjuvant chemotherapy is used after complete resection of non-small cell lung cancer (NSCLC) surgery. However, in the face of complete resection of non-small cell lung cancer with a 5-year survival rate (57% -67% in stage I: 38% -55% : Stage IIA 23% -25% Clifton F Mountain 1997), any one of the clinicians in the treatment of cancer can not remain indifferent to one-half or more than half of completely resected NSCLC due to local recurrence and long-term metastasis within 5 years after surgery. Nothing The question is whether existing treatment will provide survival benefits to patients? The answer is to look at evidence-based medicine from the latest large clinical trials, multicenter, randomized controlled trials. In this paper, “Meta-analysis of platinum-containing adjuvant chemotherapy regimen after complete resection of non-small cell lung cancer” with rigorous scientific attitude, informative data, appropriate and effective analytical methods (cumulative Meta analysis) of radical non-small cell lung cancer after surgery Whether the use of adjuvant chemotherapy were analyzed and reached preliminary conclusions. On the clinical